Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Investor Presentation (April 2011)
28 slides from Lisata Therapeutics's investor presentation, Apr 5, 2011
Slide 1: NeoStem, Inc. Investor Presentation April 2011
NEOSTEM, INC. (“NBS”) Investor Presentation April 2011
Slide 2: Forward-Looking Statements
Forward -Looking Statements Included in this presentation are “forward -looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information . Such forward -looking statements involve known and unknown risks, uncertainties and other factor
Slide 3: About NeoStem
About NeoStem NeoStem is accelerating proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transport of cells for cell-based medicine and regenerative science globally . As an international biopharmaceutical company, it has a
Slide 4: Positioned to Lead the Paradigm Shift to Cell-Based Therapeutics
About NeoStem NeoStem is Positioned to be a leader in the Paradigm Shift to Cell-Based Therapeutics 5
Slide 5: Cell-based Therapy Is the Next Frontier
Cell-based Therapy Is Considered The Next Frontier & … Is Happening Now! • Cell-based therapy approaching an inflection point, with establishment of proof-of-concept • Follow the number of cell therapeutics within the regulatory pathway (phase 1-3) • From the origins of bone marrow transplantation (
Slide 6: Case Studies in Cellular Immunity
66 Case Studies In Cellular Immunity Dendreon: Provenge for Prostate Cancer •Leukapheresis, enrichment of monocytes, NK, B and T cells •Cells incubated with antigen delivery cassette (PAP-GMCSF fusion protein) •Potency determined by measuring surface expression of CD54/ICAM -1 •Cells re-infused into
Slide 7: Progenitor Cell Therapy: An Enabling Transaction
Progenitor Cell Therapy: An Enabling Transaction In January 2011, NeoStem completed the equity -based acquisition of Progenitor Cell Therapy (PCT) Which Added Manufacturing, Regulatory Expertise and a Therapeutics Pipeline 10 years of • PCT is a World Class Cell Based experience Manufacturing Operat
Slide 8: VSEL Technology Overview
VSEL ™Technology Overview VSEL™ Technology is NeoStem’s proprietary adult stem cell technology with exclusive worldwide license from the University of Louisville • Isolated from a patients own bone marrow, heart peripheral blood, or cord blood VSEL™ • Demonstrates pluripotency and somatic imprinting
Slide 9: VSEL Technology Clinical Studies
VSEL™ Technology Clinical Studies VSEL mobilization is the body’s natural reaction to acute injury Mobilization of Bone Marrow -Derived Oct -4+ SSEA -4+Very Small Embryonic -Like Stem Cells in Patients Acute Myocardial Infarction Acute Stroke Source: W. Wojakowski, et al J. Am Coll. Cordiol . 2009;
Slide 10: NeoStem Wound Technology
NeoStem Wound Technology (Worldwide License ) Solid tissue focused treatment now being used in clinic Melanoma Double barreled syringe Back wound after surgery Spraying adult stem Wound completely healed to spray adult stem cells to Remove skin cancer cells into the wound after 7 months Foot Baselin
Slide 11: Patent & Patent Applications
Patent & Patent Applications NeoStem aggressively is seeking international patent protection for its own technologies . Additionally, NeoStem sponsors research activities at various academic institutions pursuant to which it is given the right to license exclusively certain inventions resulting from
Slide 12: Athelos: A T-Cell Strategy
Athelos : A T-Cell Strategy • Athelos is an 80% owned subsidiary of NeoStem (through PCT). Athelos is developing an autologous T regulatory cells (T-reg) therapeutic . • Athelos' T-reg therapy represents a novel approach for restoring immune balance by enhancing T-reg cell number and function . • Th
Slide 13: Proprietary Delivery Technology in China
Licensed and Are Developing Proprietary Delivery Technology in China Goal: Developing cellular therapy platform in China to generate revenues today and serve as a vehicle for expansion in the future Proprietary Technology Cells Used Currently Potential Future Indication Advancements Orthopedics MSCs
Slide 14: Validating Partnerships
Validating Partnerships Industry • Participation in Therapeutics with industry leaders Governmental • NeoStem to receive $700,000 from the U.S. Army's Medical Research and Materiel Command to advance adult stem cell therapies in treating traumatic wounds • NeoStem to receive $1.7 million from U.S. A
Slide 15: Goals of Cell Therapy Business
Goals of Cell Therapy Business • Grow revenues from process and assay development, manipulation, cryopreservation, storage, manufacturing and distribution • Expand contract cGMP manufacturing for other cell therapy centers, academic institutions and companies using China facility in development • De
Slide 16: Progressive Stem Cell Environment in China
Progressive Stem Cell Environment in China • Favorable clinical and regulatory environment – Greater receptivity toward advanced therapeutics such as stem cell therapy – Actively seeking innovative technologies and therapies from the U.S. • Large and rapidly growing Chinese health care market going
Slide 17: NeoStem's China Affiliated Entities
NeoStem’s China Affiliated Entities 1.) Network of Hospitals delivering NeoStem’s Asia licensed Adult Stem Cell technology for Orthopedics using MSCs 1.) Wendeng Hospital – Launched June 2010 2.) Shijianzhuag – Third Hospital signed December 2010 3 3.) A third hospital in Tianjin expected to sign mi
Slide 18: Suzhou Erye – Profitable & Growing
Suzhou Erye – Profitable & Growing Acquired 51% of Chinese generic therapeutics company, Suzhou Erye (1) Location Suzhou China Suzhou Erye Market Opportunity Vertically -integrated manufacturer of generic China announced $124 billion budget to improve antibiotic products and APIs with extensive heal
Slide 19: Goals of Suzhou Erye
Goals of Suzhou Erye • Complete relocation to allow doubling of manufacturing capacity; increase revenues by eliminating inefficiencies associated with transitioning to new facility • Commercialize pipeline drugs • Continue to develop distribution channels domestically as well as the export of API’s
Slide 20: China Market Strategy
China Market Strategy • Leverage Suzhou Erye platform to capture Chinese market -established operational presence in China • Accelerate growth of Suzhou Erye -Doubling manufacturing capacity -Addition of new drugs to portfolio • Build cell banking and manufacturing components to drive near-term reve
Slide 21: Summary of NeoStem Business Strategy
Summary of NeoStem Business Strategy Integrated Components Create the Foundations for Therapeutics • PCT is an Industry Leader in Cell Based Manufacturing – Pioneered the Manufacturing of Dendreon’s Provenge – Working with other Industry Leaders – Currently break even business poised to leverage vol
Slide 22: Key Investment Highlights
Key Investment Highlights • NeoStem is Diversified with Multiple Platforms Positioned to Capture the Paradigm Shift to Cell based Medicine – Differentiated Cell Therapeutics Platform Company – Core Expertise in a wide range of cell based therapeutics from dendritic Vaccines to Autlogous Stem Cell th
Slide 23: Key Executives
Key Executives NeoStem Management Team Robin Smith, MD MBA MD – Yale; MBA – Wharton CEO & Chairman of the Board Formerly President & CEO IP2M (HC multimedia), EVP & CMO HealthHelp (radiology management) Trustee of NYU Medical Center; Chairman of the Board of NYU Hospital for Joint Diseases (through
Slide 24: Board of Directors
Board of Directors NeoStem Board Members Robin Smith, MD, MBA MD – Yale; MBA – Wharton CEO & Chairman of the Board Formerly President & CEO IP2M (HC multimedia), EVP & CMO HealthHelp (radiology management) Trustee of NYU Medical Center; Chairman of the Board of NYU Hospital for Joint Diseases (throu
Slide 25: Capitalization Table
Capitalization Table NeoStem Capitalization Table Capitalization (Common Share Equivalent in 000s) Shares Outstanding % Outstanding Common Stock 78,083 63.3% Total Preferred Shares (common share equivalents) 5,300 (1) 4.3% Total Warrants (average exercise price $2.89) 25,114 20.3% Total Options (ave
Slide 26: Key Financial Metrics
Key Financial Metrics (1) Historical Income Statement ($ 000’s) Balance Sheet ($ 000’s) As of Year Ended 12/31/2010 12/31/2010 Revenue Cash & equivalents $ 15,612 Pharmaceuticals** $ 69,584 Current assets $ 46,883 Stem cell and others 237 Total assets $ 143,025 Total revenues $ 69,821 Current liabil
Slide 27: Reviewing The Opportunity
Reviewing The Opportunity … • The potential to impact public health is both realistic and substantial • Successful products already exist, and more expected will arrive within the next 5 years • The competition in this area is early and many lack the expertise, but it is rising • Opportunity to crea
Slide 28: Contact Information
Contact Information NeoStem, Inc. Robin Smith, MD, MBA Chairman & CEO Phone: (212) 584-4174 Email: rsmith@neostem .com http://www .neostem .com 29